Published in Behav Pharmacol on March 01, 2010
Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil. Neuropsychopharmacology (2011) 0.94
Psychomotor stimulation by dopamine D₁-like but not D₂-like agonists in most mouse strains. Exp Clin Psychopharmacol (2011) 0.82
Effects of the 5HT2C antagonist SB242084 on the pramipexole-induced potentiation of water contrafreeloading, a putative animal model of compulsive behavior. Psychopharmacology (Berl) (2012) 0.79
Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats. Brain Res (2011) 0.78
Activation of nociceptin/orphanin FQ peptide receptors disrupts visual but not auditory sensorimotor gating in BALB/cByJ mice: comparison to dopamine receptor agonists. Neuropsychopharmacology (2011) 0.76
MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348. Psychopharmacology (Berl) (2013) 0.76
BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats. Sci Rep (2017) 0.75
Meis1 effects on motor phenotypes and the sensorimotor system in mice. Dis Model Mech (2017) 0.75
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther (2002) 1.87
Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol Biochem Behav (1986) 1.56
Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci (2005) 1.37
Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology (2006) 1.33
Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J Pharmacol Exp Ther (2004) 1.27
Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci (2002) 1.24
Assessment of murine startle reactivity, prepulse inhibition, and habituation. Curr Protoc Neurosci (2003) 1.21
The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci (1999) 1.18
7-OH-DPAT and PD 128907 selectively activate the D3 dopamine receptor in a novel environment. Neuropsychopharmacology (2003) 1.13
Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci (2002) 1.12
Deletion of dopamine D1 and D3 receptors differentially affects spontaneous behaviour and cocaine-induced locomotor activity, reward and CREB phosphorylation. Eur J Neurosci (2005) 1.09
Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology (2003) 1.05
Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol (1996) 1.01
Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol Psychiatry (2008) 1.01
Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol (1994) 1.00
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia. Br J Pharmacol (2007) 0.99
C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice. Neuroscience (2006) 0.98
The effects of dopamine agonists on prepulse inhibition in healthy men depend on baseline PPI values. Psychopharmacology (Berl) (2005) 0.98
Amphetamine effects on startle gating in normal women and female rats. Psychopharmacology (Berl) (2009) 0.98
Contributions of dopamine D1, D2, and D3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice. Neuropsychopharmacology (2007) 0.96
The dopamine D(3) receptor Ser9Gly polymorphism modulates prepulse inhibition of the acoustic startle reflex. Biol Psychiatry (2008) 0.96
Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation. Behav Pharmacol (2008) 0.95
Apomorphine-induced prepulse inhibition disruption is associated with a paradoxical enhancement of prepulse stimulus reactivity. Neuropsychopharmacology (2004) 0.93
Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44. Pharmacol Biochem Behav (2009) 0.93
Pramipexole effects on startle gating in rats and normal men. Psychopharmacology (Berl) (2009) 0.93
The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol (1997) 0.90
The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol Biochem Behav (2007) 0.90
Repeated quinpirole treatment increases cAMP-dependent protein kinase activity and CREB phosphorylation in nucleus accumbens and reverses quinpirole-induced sensorimotor gating deficits in rats. Neuropsychopharmacology (2004) 0.89
Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. Biol Psychiatry (2007) 0.88
Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice. Neuroreport (2000) 0.87
Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST). Eur Neuropsychopharmacol (2007) 0.86
Apomorphine-induced disruption of prepulse inhibition that can be normalised by systemic haloperidol is insensitive to clozapine pretreatment. Psychopharmacology (Berl) (2004) 0.86
A single dose of methamphetamine leads to a long term reversal of the blunted dopamine D1 receptor-mediated neocortical c-fos responses in mice deficient for D2 and D3 receptors. J Biol Chem (2000) 0.85
Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice. Br J Pharmacol (2009) 0.84
Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice. Prog Neuropsychopharmacol Biol Psychiatry (1998) 0.84
QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine. Neuropharmacology (2006) 0.83
Effects of selective dopamine D1-like and D2-like agonists on prepulse inhibition of startle in inbred C3H/HeJ, SPRET/EiJ, and CAST/EiJ mice. Psychopharmacology (Berl) (2006) 0.82
The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice. Pharmacol Biochem Behav (2004) 0.82
Enhanced effect of dopaminergic stimulation on prepulse inhibition in mice deficient in the alpha subunit of G(z). Psychopharmacology (Berl) (2005) 0.82
Effect of methamphetamine on cognition and repetitive motor behavior of mice deficient for dopamine D2 and D3 receptors. Ann N Y Acad Sci (2004) 0.81
The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Psychopharmacology (Berl) (2004) 0.81
Quinelorane, a dopamine D3/D2 receptor agonist, reduces prepulse inhibition of startle and ventral pallidal GABA efflux: time course studies. Pharmacol Biochem Behav (2008) 0.80
Effects of acute "binge" cocaine on mRNA levels of mu opioid receptor and neuropeptides in dopamine D1 or D3 receptor knockout mice. Synapse (2007) 0.80
Antagonism of cocaine's pharmacological effects by the stimulant dopaminergic antagonists, (+)-AJ76 and (+)-UH232. Brain Res (1992) 0.80
Parametric approaches towards understanding the effects of the preferential D3 receptor agonist pramipexole on prepulse inhibition in rats. Pharmacol Biochem Behav (2010) 0.79
Differential susceptibility to ethanol and amphetamine sensitization in dopamine D3 receptor-deficient mice. Psychopharmacology (Berl) (2008) 0.79
Endomorphin-1, an endogenous mu-opioid receptor agonist, improves apomorphine-induced impairment of prepulse inhibition in mice. Peptides (2003) 0.78
Does angiotensin interact with dopaminergic mechanisms in the brain to modulate prepulse inhibition in mice? Neuropharmacology (2007) 0.77
Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice. Psychopharmacology (Berl) (2002) 0.77
Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist. Pharmacol Biochem Behav (1998) 0.77
KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia. Pharmacol Biochem Behav (2005) 0.77
Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.77
The global burden of group A streptococcal diseases. Lancet Infect Dis (2005) 13.58
Gaps in policy-relevant information on burden of disease in children: a systematic review. Lancet (2005) 4.64
Indoor air pollution from unprocessed solid fuel use and pneumonia risk in children aged under five years: a systematic review and meta-analysis. Bull World Health Organ (2008) 3.82
Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell (2013) 3.26
Habituation revisited: an updated and revised description of the behavioral characteristics of habituation. Neurobiol Learn Mem (2008) 3.23
Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull (2006) 2.92
Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry (2007) 2.91
Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) (2008) 2.64
Risk of low birth weight and stillbirth associated with indoor air pollution from solid fuel use in developing countries. Epidemiol Rev (2010) 2.63
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov (2012) 2.44
Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry (2006) 2.25
Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology (2008) 2.16
Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry (2011) 1.93
A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry (2006) 1.93
Pneumonia case-finding in the RESPIRE Guatemala indoor air pollution trial: standardizing methods for resource-poor settings. Bull World Health Organ (2007) 1.90
The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull (2006) 1.88
Global initiatives for improving hospital care for children: state of the art and future prospects. Pediatrics (2008) 1.73
The prevalence of hypoxaemia among ill children in developing countries: a systematic review. Lancet Infect Dis (2009) 1.73
Methodological and quality issues in epidemiological studies of acute lower respiratory infections in children in developing countries. Int J Epidemiol (2004) 1.72
A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry (2009) 1.69
Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther (2009) 1.67
Comparative impact assessment of child pneumonia interventions. Bull World Health Organ (2009) 1.49
Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry (2003) 1.48
Development of paediatric quality of inpatient care indicators for low-income countries - A Delphi study. BMC Pediatr (2010) 1.44
Studies in genetically modified mice suggest novel mechanisms of mood regulation. Biol Psychiatry (2010) 1.38
Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology (2006) 1.33
Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS. Schizophr Bull (2008) 1.32
Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry (2013) 1.30
siRNA stabilization prolongs gene knockdown in primary T lymphocytes. Eur J Immunol (2008) 1.30
A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev (2007) 1.29
Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res (2008) 1.29
Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One (2012) 1.28
Preattentive sensory processing as indexed by the MMN and P3a brain responses is associated with cognitive and psychosocial functioning in healthy adults. J Cogn Neurosci (2007) 1.28
Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry (2003) 1.28
Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One (2012) 1.27
Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci (2004) 1.26
Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res (2006) 1.25
Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci (2002) 1.24
5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology (2009) 1.24
Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res (2009) 1.20
The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One (2009) 1.20
Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry (2008) 1.19
The quantitative assessment of motor activity in mania and schizophrenia. J Affect Disord (2010) 1.18
Advances in endophenotyping schizophrenia. World Psychiatry (2008) 1.18
Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder. Neuropsychopharmacology (2012) 1.17
Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. Psychiatry Res (2003) 1.17
Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models. Neurosci Biobehav Rev (2013) 1.16
The active site of cellobiohydrolase Cel6A from Trichoderma reesei: the roles of aspartic acids D221 and D175. J Am Chem Soc (2002) 1.15
The relationship of age to prepulse inhibition and habituation of the acoustic startle response. Biol Psychol (2003) 1.15
A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics. Int J Neuropsychopharmacol (2006) 1.15
GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology (Berl) (2009) 1.14
Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology (2007) 1.13
Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol (2013) 1.13
Distinguishing malaria from severe pneumonia among hospitalized children who fulfilled integrated management of childhood illness criteria for both diseases: a hospital-based study in Mozambique. Am J Trop Med Hyg (2011) 1.12
The mouse attentional-set-shifting task: a method for assaying successful cognitive aging? Cogn Affect Behav Neurosci (2010) 1.11
Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) (2003) 1.11
The C terminus (amino acids 75-94) and the linker region (amino acids 42-54) of the Ca2+-binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibers. J Biol Chem (2003) 1.11
Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS One (2009) 1.10
Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Res (2004) 1.10
Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry (2006) 1.09
Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice. Biol Psychiatry (2008) 1.07
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology (2011) 1.06
Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophr Res (2002) 1.06
Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology (2003) 1.05
Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis--a longitudinal study. Eur Arch Psychiatry Clin Neurosci (2004) 1.05
Strain differences in the gating-disruptive effects of apomorphine: relationship to gene expression in nucleus accumbens signaling pathways. Biol Psychiatry (2008) 1.04
Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull (2005) 1.04
Animal models of schizophrenia. Curr Top Behav Neurosci (2010) 1.04
Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol (2011) 1.04
Heart rate variability in bipolar mania and schizophrenia. J Psychiatr Res (2009) 1.03
Prepulse inhibition and P50 suppression: commonalities and dissociations. Psychiatry Res (2006) 1.03
Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biol Psychiatry (2012) 1.02
Repeated assessment of exploration and novelty seeking in the human behavioral pattern monitor in bipolar disorder patients and healthy individuals. PLoS One (2011) 1.02
Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Res (2010) 1.02
The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacol Biochem Behav (2010) 1.02
Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) (2003) 1.02
CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology (2008) 1.02
Sept5 deficiency exerts pleiotropic influence on affective behaviors and cognitive functions in mice. Hum Mol Genet (2009) 1.01
Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology (2007) 1.01
Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. J Psychopharmacol (2011) 1.00
Life-threatening bleeding after dental extraction in a hemophilia A patient with inhibitors to factor VIII: a case report. J Oral Maxillofac Surg (2003) 1.00
GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology (2002) 1.00
RNA interference: PCR strategies for the quantification of stable degradation-fragments derived from siRNA-targeted mRNAs. Biomol Eng (2004) 1.00
Information-processing deficits and cognitive dysfunction in panic disorder. J Psychiatry Neurosci (2005) 0.99
Treating auditory hallucinations by transcranial magnetic stimulation: a randomized controlled cross-over trial. Neuropsychobiology (2006) 0.99
Action of modafinil--increased motivation via the dopamine transporter inhibition and D1 receptors? Biol Psychiatry (2010) 0.99
The challenge of connecting the dots in the B.R.A.I.N. Neuron (2013) 0.99
Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res (2010) 0.99
Predictors of risk and resilience for posttraumatic stress disorder among ground combat Marines: methods of the Marine Resiliency Study. Prev Chronic Dis (2012) 0.98
Perceptual measurement in schizophrenia: promising electrophysiology and neuroimaging paradigms from CNTRICS. Schizophr Bull (2011) 0.98
Amphetamine effects on startle gating in normal women and female rats. Psychopharmacology (Berl) (2009) 0.98
Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders. Curr Top Behav Neurosci (2012) 0.97
The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behav Brain Res (2011) 0.97
Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders. Hum Mol Genet (2010) 0.97
Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol (2010) 0.97
Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci Biobehav Rev (2010) 0.97
Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res (2011) 0.97